The brokerage says margins and asset quality are set to normalize going ahead and drive divergence in profitability based on the franchise strength

S&P says the improvement is driven by broad-based earnings growth and increased financial discipline

Citi says Indian automaker’s 1QFY25 results were above its estimates, driven by strong margin expansion despite escalated discounts

HSBC says value retailing remains the core positioning of DMart and will be central to all its offline and online retail endeavors

Morgan Stanley raises its target price on Indian aviation major IndiGo to 5,245 rupees from 5,142 rupees per share following its quarterly results

Bajaj Auto last week launched the world’s first CNG-powered motorcycle Freedom 125

Morgan Stanley says the growth will be driven by new business cycles, new cash flow streams emerge, and higher valuation multiples

Equirus Securities initiates coverage on FSN E-Commerce with Long rating and a target price of 240 rupees per share

Jefferies says ICICI Bank stays among its top picks in the financial sector amid healthy deposit growth and slower cost growth

Bernstein initiates coverage on IndusInd Bank and Muthoot Finance with Outperform ratings

CLSA expects private sector banks, which have been stock market laggards, to give better returns amid good business outlook and inexpensive valuations

Jefferies says acquisition of Hyderabad-based cement maker moves Ambuja, a part of Adani Group, to top three players in the south region

Morgan Stanley expects sector tailwinds and robust order backlog to drive sustainable growth in the company’s core EMS business

Nomura expects Indian equity market to react positively in near term, if exit polls, which suggest return of BJP, turn to actual results on 4 June

S&P expects broad continuity in economic reforms and fiscal policies regardless of the general election outcome on 4 June

Jefferies upbeat on GMR Airports’ prospects due to passenger traffic growth and travel retail opportunity

Jefferies upbeat on JB Chemicals due to its strong execution capabilities, possibilities of positive surprise from CDMO business in the medium term

Jefferies says Mankind Pharma has the potential to consistently outperform industry growth and improve margins consistently